DEVELOPMENT OF VACCINE AGAINST CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIA
Asian Journal of Advances in Medical Science, Volume 3, Issue 2,
Page 13-21
Abstract
The pandemic declaration of Covid-19 infection by World Health Organization (WHO) and ensuing boundless morbidities and mortalities in practically all nations of the world prompted the innovative work to discover an immunization against SARS-CoV2 infection. Typically any new vaccine takes 10–15 y time. In pandemic circumstance, the whole cycle of vaccine development including clinical preliminaries gets shortened and optimized to 10–14 month time. i.e. the quest for vaccine against Covid-19 is going on at a high speed coming with the good news of two vaccines Covishield and Covaxin. This review aims at highlighting the present stages of development of vaccinesin Indian scenario.
Keywords:
- Coronavirus
- covaxin
- covishield
- clinical
- vaccines.
How to Cite
RATHER, R. A., ISLAM, T., REHMAN, I. U., & PANDEY, D. (2021). DEVELOPMENT OF VACCINE AGAINST CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIA. Asian Journal of Advances in Medical Science, 3(2), 13-21. Retrieved from https://www.mbimph.com/index.php/AJOAIMS/article/view/1949
References
Perlman S. Another Decade, Another coronavirus. N Engl J Med; 2020.
Available:https://doi.org/10.1056/ NEJMe2001126 PMID: 31978944.
Wang C. et al. A novel coronavirus outbreak of global health concern. Lancet; 2020.
Available:https://doi.org/10.1016/S0140-6736(20)30185-9PMID:31986257.
Guan W. j. et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720.
Guan WJ. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med; 2020.
Available:https://doi.org/10.1056/NEJMoa2002032PMID:32109013.
Chen H. et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–15.
Available:https://doi.org/10.1016/S0140-6736(20)30360-3PMID:32151335.
Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513.
Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 2020;20:529−536.
Bhatraju PK. et al. Covid-19 in critically ill patients in the Seattle region—case series. New England Journal of Medicine; 2020.
Zhang W. et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386.
Available:https://doi.org/10.1080/22221751.2020.1729071PMID:32065057;PubMedCentralPMCID:PMC7048229.
Van Doremalen N. et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med; 2020.
Available:https://doi.org/10.1056/NEJMc2004973PMID:32182409.
Li Q. et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med; 2020.
Available:https://doi.org/10.1056/NEJMoa2001316PMID:31995857.
Yang Y. et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv; 2020.
Available:https://doi.org/10.1016/j.cmi.2020.02.005PubMedPMID:32058086.
Porcheddu R. et al. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14(2):125–8.
Available:https://doi.org/10.3855/jidc.12600PMID:32146445.
Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet; 2020.
Available:https://doi.org/10.1016/S01406736(20)30627-9PMID:32178769.
Lu X. et al. SARS-CoV-2 Infection in Children. N Engl J Med; 2020.
Available:https://doi.org/10.1056/NEJMc2005073PMID:32187458.
Schmid MB et al. COVID-19 in pregnant women. Lancet Infect Dis; 2020.
Available:https://doi.org/10.1016/S1473-3099(20)30175-4PMID:32197098.
Rouse BT, Sehrawat S. Immunity and immunopathology to Viruses: What Decides the Outcome? Nat. Rev. Immunol. 2010;10:514−526.
Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 2010;10:338−349.
Zhao J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis; 2020.
DOI: 10.1093/cid/ciaa344.
Juno JA. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020;26:1428−1434.
Dhama K. et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccine Immunotherpy; 2020.
Available:https://doi.org/10.1080/21645515.2020.1735227.
Ning et al. Subunit vaccines against emerging pathogenic human coronaviruses. Frontiers in Microbiology; 2020.
Available:https://doi. org/10.3389/fmicb.2020.00298.
Le Thanh T et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19: 305–6.
Le Tung. et al. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery. 2020;19(5):305–306.
Gupta V et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology. 2006;347(1):127–139.
Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. 2020;495–500.
Available:https:// doi.org/10.1002/jmv.25698.
COVID-19 vaccine. Vaccine information, ICMR New Delhi - COVID-19 Vaccine; 2020.
Available:https://vaccine.icmr.org.in/covid-19-vaccine.
Panacea Biotec, Refana Announce Landmark Collaboration for Covid- 19 Vaccine. Panacea Biotec; 2020.
Available:https://www.panaceabiotec.com/press-release-panacea-biotec-and-refana-announce-landmark-collaboration-for-covid-19-vaccine.
Mullard A. COVID-19 vaccine development pipeline gears up. The Lancet. 2020;395(10239):1751-1752.
Douglas RG, Samant VB. The vaccine industry. In: Plotkins SA, Orenstein WA, Offit PA, editors. Vaccine. 6th ed. China: Saunders Elsevier. 2013;33–43.
Lauer SA. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine; 2020.
Available:https://doi.org/10.1056/ NEJMe2001126 PMID: 31978944.
Wang C. et al. A novel coronavirus outbreak of global health concern. Lancet; 2020.
Available:https://doi.org/10.1016/S0140-6736(20)30185-9PMID:31986257.
Guan W. j. et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720.
Guan WJ. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med; 2020.
Available:https://doi.org/10.1056/NEJMoa2002032PMID:32109013.
Chen H. et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–15.
Available:https://doi.org/10.1016/S0140-6736(20)30360-3PMID:32151335.
Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513.
Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 2020;20:529−536.
Bhatraju PK. et al. Covid-19 in critically ill patients in the Seattle region—case series. New England Journal of Medicine; 2020.
Zhang W. et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386.
Available:https://doi.org/10.1080/22221751.2020.1729071PMID:32065057;PubMedCentralPMCID:PMC7048229.
Van Doremalen N. et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med; 2020.
Available:https://doi.org/10.1056/NEJMc2004973PMID:32182409.
Li Q. et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med; 2020.
Available:https://doi.org/10.1056/NEJMoa2001316PMID:31995857.
Yang Y. et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv; 2020.
Available:https://doi.org/10.1016/j.cmi.2020.02.005PubMedPMID:32058086.
Porcheddu R. et al. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14(2):125–8.
Available:https://doi.org/10.3855/jidc.12600PMID:32146445.
Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet; 2020.
Available:https://doi.org/10.1016/S01406736(20)30627-9PMID:32178769.
Lu X. et al. SARS-CoV-2 Infection in Children. N Engl J Med; 2020.
Available:https://doi.org/10.1056/NEJMc2005073PMID:32187458.
Schmid MB et al. COVID-19 in pregnant women. Lancet Infect Dis; 2020.
Available:https://doi.org/10.1016/S1473-3099(20)30175-4PMID:32197098.
Rouse BT, Sehrawat S. Immunity and immunopathology to Viruses: What Decides the Outcome? Nat. Rev. Immunol. 2010;10:514−526.
Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 2010;10:338−349.
Zhao J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis; 2020.
DOI: 10.1093/cid/ciaa344.
Juno JA. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020;26:1428−1434.
Dhama K. et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccine Immunotherpy; 2020.
Available:https://doi.org/10.1080/21645515.2020.1735227.
Ning et al. Subunit vaccines against emerging pathogenic human coronaviruses. Frontiers in Microbiology; 2020.
Available:https://doi. org/10.3389/fmicb.2020.00298.
Le Thanh T et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19: 305–6.
Le Tung. et al. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery. 2020;19(5):305–306.
Gupta V et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology. 2006;347(1):127–139.
Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. 2020;495–500.
Available:https:// doi.org/10.1002/jmv.25698.
COVID-19 vaccine. Vaccine information, ICMR New Delhi - COVID-19 Vaccine; 2020.
Available:https://vaccine.icmr.org.in/covid-19-vaccine.
Panacea Biotec, Refana Announce Landmark Collaboration for Covid- 19 Vaccine. Panacea Biotec; 2020.
Available:https://www.panaceabiotec.com/press-release-panacea-biotec-and-refana-announce-landmark-collaboration-for-covid-19-vaccine.
Mullard A. COVID-19 vaccine development pipeline gears up. The Lancet. 2020;395(10239):1751-1752.
Douglas RG, Samant VB. The vaccine industry. In: Plotkins SA, Orenstein WA, Offit PA, editors. Vaccine. 6th ed. China: Saunders Elsevier. 2013;33–43.
Lauer SA. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine; 2020.
-
Abstract View: 2617 times
PDF Download: 1590 times
